<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201445</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-418-4279</org_study_id>
    <secondary_id>2017-000402-38</secondary_id>
    <nct_id>NCT03201445</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease</brief_title>
  <acronym>MANTA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the testicular safety of filgotinib in&#xD;
      adult males with moderately to severely active inflammatory bowel disease.&#xD;
&#xD;
      Results of this study may be pooled with the results of a separate study being conducted in&#xD;
      participants with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or&#xD;
      non-radiographic axial spondyloarthritis (Protocol GLPG0634-CL-227; NCT03926195) with the&#xD;
      same objective. The total planned number of participants in both studies combined will be up&#xD;
      to approximately 250 participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Motile Sperm at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Motile Sperm at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sperm Count at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sperm Count at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sperm Concentration at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sperm Concentration at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ejaculate Volume at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ejaculate Volume at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percent Normal Sperm Morphology at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percent Normal Sperm Morphology at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Part A (Filgotinib or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive double-blind filgotinib or placebo for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Filgotinib or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on inflammatory bowel disease response status and sperm parameters, participants will continue on the blinded treatment for up to an additional 13 weeks or discontinue blinded study drug and commence open-label filgotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Filgotinib Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive open-label filgotinib for up to 13 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monitoring Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose sperm parameters meet a pre- specified decrease threshold at any time during the study, regardless of inflammatory bowel disease response status, will discontinue study drug and receive standard of care therapy in the Monitoring Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Term Extension Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants qualifying to enter the Long Term Extension Phase will receive either open-label filgotinib or blinded study drug for up to 195 weeks based on the individual's response criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>200 mg tablet administered orally once daily</description>
    <arm_group_label>Long Term Extension Phase</arm_group_label>
    <arm_group_label>Open-Label Filgotinib Phase</arm_group_label>
    <arm_group_label>Part A (Filgotinib or Placebo)</arm_group_label>
    <arm_group_label>Part B (Filgotinib or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Long Term Extension Phase</arm_group_label>
    <arm_group_label>Part A (Filgotinib or Placebo)</arm_group_label>
    <arm_group_label>Part B (Filgotinib or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care therapy options may include but are not limited to methotrexate</description>
    <arm_group_label>Monitoring Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male participants who are between the ages of 21 and 65 (inclusive) on the day of&#xD;
             signing informed consent&#xD;
&#xD;
          -  Documented diagnosis of ulcerative colitis (UC) or Crohn's Disease (CD) of at least 4&#xD;
             months. Endoscopic and histopathologic documentation of UC or CD.&#xD;
&#xD;
          -  Have moderately to severely active UC or CD&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Previously or currently documented problems with male reproductive health&#xD;
&#xD;
          -  Current use of sulfasalazine or its use within the 26 weeks leading up to Screening;&#xD;
             sulfasalazine is not permitted at any point during the study&#xD;
&#xD;
          -  Current use of corticosteroids at a dosage of &gt; 20 mg/day of prednisone or equivalent&#xD;
             at randomization&#xD;
&#xD;
          -  Indeterminate colitis, ischemic colitis, fulminant colitis, isolated ulcerative&#xD;
             proctitis, or toxic mega colon&#xD;
&#xD;
          -  Active tuberculosis (TB) or untreated latent tuberculosis&#xD;
&#xD;
          -  Use of concomitant prohibited medications as outlined by protocol&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Crohn's and Colitis Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>One Health Research Clinic, Inc</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien - Universitatsklinik fur Innere Medizin III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surat Institute of Digestive Sciences</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth GS medical college and KEM hospital</name>
      <address>
        <city>Parel</city>
        <state>Mumbai</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaizen Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Medical college &amp; AG Hospitals</name>
      <address>
        <city>Bīkaner</city>
        <zip>334001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaja Agrasen Hospital</name>
      <address>
        <city>Dehli</city>
        <zip>110026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SR Kalla Memorial Gastro and General Hospital</name>
      <address>
        <city>Jaipur</city>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Medical College and Hospital</name>
      <address>
        <city>Jaipur</city>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Om Sai Onco Surgery Center</name>
      <address>
        <city>Kolhapur</city>
        <zip>416006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post Graduate Medical Education and Research (IPGMER)</name>
      <address>
        <city>Kolkata</city>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radha Krishna Critical Care &amp; General Hospital</name>
      <address>
        <city>Kota</city>
        <zip>324005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rahate Surgical Hospital</name>
      <address>
        <city>Nagpur</city>
        <zip>440008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Hospital and Heart Centre</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batra Hospital and Medical Research Center</name>
      <address>
        <city>New Delhi</city>
        <zip>110062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri Griraj Multispeciality Hospital</name>
      <address>
        <city>Rajkot</city>
        <zip>360005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Hospital</name>
      <address>
        <city>Secunderabad</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Gastroenterology &amp; Liver Disease, Sunshine Hospitals</name>
      <address>
        <city>Secunderabad</city>
        <zip>50003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAPS Pramukh Swami Hospital</name>
      <address>
        <city>Surat</city>
        <zip>395009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Hospital</name>
      <address>
        <city>Vadodara</city>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samvedna Hospital</name>
      <address>
        <city>Varanasi</city>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych Cinsante S.C Ewa Galczak-Nowak</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp.z o.o</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodyclinic Alicja Pasnik</name>
      <address>
        <city>Warsaw</city>
        <zip>00-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Familia, Centrum Badan Profilaktyki i Leczenia</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Policlinica Dr. Citu S.R.L - Gastroenterologie</name>
      <address>
        <city>Timisoara</city>
        <zip>300594</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olla-Med, Llc</name>
      <address>
        <city>Moscow</city>
        <zip>105554</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution, Pensa Regional Clinical Hospital n.a N.N Burdenko</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;Rostov State Medical University&quot; of the Ministry of Health of Russian Fedn.</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Healthcare Institution &quot;City Hospital # 26&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;Regional Hospital of War Veterans&quot;, Therapeutic Department No. 1</name>
      <address>
        <city>Kharkiv</city>
        <zip>61137</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #18, Proctology Department</name>
      <address>
        <city>Kiev</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital of War Veterans, Therapeutics Department No. 2</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital named after M.I. Pirogov, Gastroenterology Department</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center LLC &quot;Health Clinic&quot;, Medical Clinical Investigational Center</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital of War Veterans, Therapeutics Department No.1</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municupal Institution &quot;Zaporizhzhia City Multidisciplinary Clinic #9&quot; Gastrointestinal Surgery Department,</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Zaporizhzhia Regional Clinical Hospital&quot; of Zaporizhzhia Regional Council,</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>India</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <disposition_first_submitted>July 27, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>July 27, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 2, 2021</disposition_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

